Acurx (ACXP) Pharmaceuticals announced that a new patent has been granted by the Australian Patent Office. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of- matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese patent, one Indian patent, and now an Australian patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?
- Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat
- Acurx’s ibezapolstat receives positive EMA opinion in C. difficile infection
- Acurx Pharmaceuticals Increases Authorized Common Stock Shares
- Acurx Pharmaceuticals Shareholders Approve Key Issuance Plans